Novel Anti-BCMA Therapy Induces Response in Heavily Pretreated Multiple Myeloma

Patients with multiple myeloma (MM) often face relapsed/refractory disease despite initial responses to firstline treatment. B-cell maturation antigen (BCMA) has emerged as a promising target for the treatment of MM.

Belantamab mafodotin is an experimental antibody-drug conjugate that targets BCMA that initially showed activity as a single agent in relapsed/refractory MM. In the multicenter, phase II, ongoing DREAMM-2 study, 31% of patients (n=30) who received belantamab mafodotin 2.5 mg/kg and 34% (n=34) who received belantamab mafodotin 3.4 mg/kg achieved an overall response, including three complete responses.

Paul G. Richardson, MD, the clinical program leader and director of clinical research at the Jerome Lipper Multiple My­eloma Center at the Dana-Farber Cancer Institute and RJ Corman Professor of Med­icine at Harvard Medical School, discussed the outcomes of the DREAMM-2 study and how he sees belantamab mafodotin impacting the MM treatment landscape.

Read More